October 21, 2025 7:56am

Framing today’s main takeaway; volatility, volume and share pricing!

The peril facing the cell and gene therapy sector isn’t just applications of macro market econs, sentiment or algorithms within electronic trading; it’s losing highly reliable, accurate and transparent data. Think of it as the difference between flying into a storm versus flying into the same storm completely blind. To understand just how catastrophic this could be, it helps to follow RMi that lends to the moment

News: Arrowhead Pharmaceuticals (ARWR +$0.04 to $38.51) a global licensing and collaboration agreement with Novartis (NVS), previously announced on 9/2/25, has now closed.

Pre-open Signals: 3 Positive and 6 Negative Indications

Never leave an investor uninformed … I say what others won’t, so you can do what others can’t!

Remember that overnight and pre-open actions’ futures and markets doesn’t necessarily translate into actual trading in today’s market session.

Monday night’s … RMi Closing Bell: Rational exuberance … https://www.regmedinvestors.com/articles/14157   

investor sentiment is buoyed by expectations that the Federal Reserve will cut rates by another 1/4-point at its late October meeting. Friday’s upcoming CPI report could be key in shaping that decision, and thus will be critical for markets.

 

Reiterating, Why and WHAT I am focused on ... “Retail investors have doubled their influence in the stock market over the last 15 years. According to data from the Blackrock's fundamental equities team, retail investors now account for 20.5% of daily trading volume in US stocks, up from 10.1% in 2010. High-frequency trading accounts for 11.6% of US trading volume, up from 1.5% 15 years ago.”

 

Tuesday: The pre-open Dow futures are DOWN -0.07% or (-32 points), the S&P futures are DOWN -0.04% or (-3 points) and the Nasdaq futures are DOWN -0.09% or (-21 points)

  • Stock futures are down although basically flat on Tuesday, 10/21
  • European markets were mixed although retreating,
  • Asia-Pacific markets opened higher, Indian markets are closed for a holiday.

 

Henry’omics: We need to more than consider the market’s setting to grasp the micro re “our” universe of cell and gene therapy companies

  • Monday: The Dow closed UP +515.97 points or +1.12%, the S&P closed UP +71.12 points or +1.07% while the Nasdaq closed UP +310.568 points or +1.37%
  • Friday: The Dow closed UP +238.37 points or +0.52%, the S&P closed UP +34.94 points or +0.53% while the Nasdaq closed UP +117.437 points or +0.52%
  • Last week: the S&P 500 is up +1.7%, the Dow added +1.6% week to date, while the Nasdaq gained +2.1%.
  • Ther previous week: the Dow was down -2%, the S&P down -1% and the Nasdaq +1%,
  • Last month and Q3’s numbers, the S&P 500 Q was up +7% and the month -4.2%, the Nasdaq’s Q is up +11% and the month +5% while the Dow’s Q is up +5% and the month +1%

 

Q4 – 1 neutral, 8 positive and 5 negative closes

  • Q3 – September, 1 holiday, 9 negative and 12 positive closes; August - 11 negative and 9 positive closes; July – 1 market holiday, 13 positive and 9 negative closes

 

Companies in my headlights – It’s your decision; I provide ideas and context

I post about “indication intelligence” looking toward investment conferences … to assist investors with insight into sector vulnerabilities and strengths.  A dictionary definition of “indicate” refers to something less than a certainty; an indication could be a signal of being oversold or overbought, a recommendation, or grounds for inferring or a basis for believing.

  • October began with a government shutdown and much fewer econs… along with the usual ups, downs
  • Now uncertainty rules

Info:

Alnylam Pharmaceuticals (ALNY) closed up +$9.55 after Friday’s +$0.60 with a positive +$0.28 or +0.06% pre-open

IQV Holdings (IQV) closed up +$7.65 after Friday’s -$1.20 with a negative -$0.15 or -0.07% pre-open

uniQure NV (QURE) closed up +$5.92 after Friday’s -$1.99 with a negative -$0.54 or -0.84% pre-open

CRISPR Therapeutics (CRSP +$4.82 after Friday’s +$0.72 with a negative -$0.36 or -0.49% pre-open

Beam Therapeutics (BEAM) closed up +$4.64 after Friday’s +$0.19 with a positive +$0.39 or +1.27% pre-open

Intellia Therapeutics (NTLA) closed up +$3.23 with a negative -$0.10 or -0.36% pre-open

BioNTech (BNTX +$2.81 after Friday’s +$0.06 with a negative -$0.84 or -0.78% pre-open

Cellectis SA (CLLS) closed down -$0.03 with a negative -$0.29 or -7.34% pre-open

Moderna (MRNA) closed up +$1,23 after Friday’s -$1.13 with a positive +$0.04 or +0.15% pre-open

 

The BOTTOM LINE: I’m opening with another mantra … If you understand probabilities, the inevitable is easier to maneuver

The shutdown enters its 21th day today, with lawmakers still unable to agree on a funding bill …

  • The shutdown has slammed the brakes on crucial inflation and jobs data key to the Fed's decision making; but the Bureau of Labor Statistics is set to release September's Consumer Price Index, on Friday after a delay of more than a week.

Welcome to my world of defining the “grey’ in our universe!

  • “I hate to be so negative or contrarian but, this is a NO spin zone and truth is its product; I can always be WRONG but, I am mostly EARLY!”
  • I am more frequently right than consequentially wrong; if I wanted to be liked, I wouldn’t have been an analyst/journalist.

 

October: understand the new “flow” …

New week:

  • 10/20 - Monday closed positive with 34 positive, 4 negative and 2 flats

Last week:

  • 10/17 - Friday closed negative with 11 positive, 28 negative and 1 flat
  • 10/16 - Thursday closed negative with 17 positive, 22 negative and 1 flat
  • 10/15 - Wednesday closed positive with 31 positive, 9 negative and 1 flat
  • 10/14 - Tuesday closed positive with 28 positive, 12 negative and 0 flat
  • 10/13 – Monday closed neutral with 20 positive, 20 negative and 0 flat

 

Q3 Earnings are in the front-view mirror; we are about to start again …!

  • Sector Q3 earnings begin with IQV Holdings (IQV) on 10/28, MiMedx (MDXG) Ionis Pharmaceuticals IONS), AxoGen AXGN) on 10/29 with Moderna (MRNA) on 11/6

 

Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice. All investments are subject to risks. Investors should consider investment objectives.

Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors.  All investments are subject to risks. Investors should consider investment objectives.  Regulation Analyst Certification (Reg AC):

The research analyst primarily responsible for the content of this report certifies the following under Reg AC: I hereby certify that all views expressed in this report accurately reflect my personal views about the subject company or companies and it’s or their securities. I also certify that no part of my compensation was, is or will be, directly or indirectly, related to the specific recommendations or views expressed.